NZ528868A - Use of bile acid or bile salt fatty acid conjugates - Google Patents
Use of bile acid or bile salt fatty acid conjugatesInfo
- Publication number
- NZ528868A NZ528868A NZ528868A NZ52886802A NZ528868A NZ 528868 A NZ528868 A NZ 528868A NZ 528868 A NZ528868 A NZ 528868A NZ 52886802 A NZ52886802 A NZ 52886802A NZ 528868 A NZ528868 A NZ 528868A
- Authority
- NZ
- New Zealand
- Prior art keywords
- acid
- bile
- use according
- general formula
- fatty
- Prior art date
Links
- 239000003613 bile acid Substances 0.000 title claims abstract description 15
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 14
- 239000000194 fatty acid Substances 0.000 title claims abstract description 14
- 239000003833 bile salt Substances 0.000 title claims abstract description 13
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 42
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 24
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 23
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 14
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 36
- 235000005911 diet Nutrition 0.000 description 30
- 230000037213 diet Effects 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 241000699800 Cricetinae Species 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 9
- 230000000927 lithogenic effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 5
- 239000004380 Cholic acid Substances 0.000 description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 5
- 229960002471 cholic acid Drugs 0.000 description 5
- 235000019416 cholic acid Nutrition 0.000 description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RPKLZQLYODPWTM-UHFFFAOYSA-N methyl 15-acetoxy(10),13E-ent-halimadien-18-oate Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RPKLZQLYODPWTM-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL142650A IL142650A (en) | 1998-04-08 | 2001-04-17 | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| PCT/IL2002/000303 WO2002083147A1 (en) | 2001-04-17 | 2002-04-15 | Use of bile acid or bile salt fatty acid conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ528868A true NZ528868A (en) | 2005-09-30 |
Family
ID=11075322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ528868A NZ528868A (en) | 2001-04-17 | 2002-04-15 | Use of bile acid or bile salt fatty acid conjugates |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7501403B2 (enExample) |
| EP (2) | EP1790346B1 (enExample) |
| JP (1) | JP4324706B2 (enExample) |
| KR (1) | KR100883080B1 (enExample) |
| CN (1) | CN1259918C (enExample) |
| AT (2) | ATE432705T1 (enExample) |
| AU (2) | AU2002307771B2 (enExample) |
| BR (1) | BR0208924A (enExample) |
| CA (2) | CA2703688C (enExample) |
| CY (1) | CY1106853T1 (enExample) |
| CZ (2) | CZ309042B6 (enExample) |
| DE (2) | DE60220775T2 (enExample) |
| DK (2) | DK1379254T3 (enExample) |
| EA (1) | EA007565B1 (enExample) |
| ES (2) | ES2289137T3 (enExample) |
| HU (1) | HU230548B1 (enExample) |
| IL (1) | IL142650A (enExample) |
| MX (1) | MXPA03009553A (enExample) |
| NO (2) | NO333910B1 (enExample) |
| NZ (1) | NZ528868A (enExample) |
| PL (2) | PL205057B1 (enExample) |
| PT (2) | PT1790346E (enExample) |
| UA (1) | UA78699C2 (enExample) |
| WO (1) | WO2002083147A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| ES2709489T3 (es) * | 2007-07-25 | 2019-04-16 | Univ Graz Medizinische | Uso de ácidos nor-biliares en el tratamiento de arteriosclerosis |
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| KR20190062609A (ko) * | 2009-01-12 | 2019-06-05 | 바이오키어 인코포레이티드 | 당뇨병 치료 조성물 및 치료방법 |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
| WO2010086864A1 (en) | 2009-02-02 | 2010-08-05 | Galmed International Ltd. | Methods and compositions for treating alzheimer's disease |
| US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| WO2013166176A1 (en) * | 2012-05-01 | 2013-11-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and fxr agonists; compositions and method of uses |
| CN103571617A (zh) * | 2012-07-26 | 2014-02-12 | 丰益(上海)生物技术研发中心有限公司 | 改进的动物油脂加工工艺 |
| ES2701077T3 (es) | 2012-11-29 | 2019-02-20 | St Pharm Co Ltd | Conjugado de oligómero de ácido biliar para un nuevo transporte vesicular y uso del mismo |
| IL227890A0 (en) * | 2013-08-08 | 2014-01-30 | Galderm Therapeutics Ltd | Antiaging compounds containing bile acid and fatty acid conjugates |
| LT3077047T (lt) * | 2013-12-04 | 2019-08-26 | Galmed Research & Development Ltd. | Aramcholio druskos |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| WO2016199137A1 (en) * | 2015-06-10 | 2016-12-15 | Galmed Research And Development Ltd. | Low dose compositions of aramchol salts |
| CN106413719A (zh) * | 2014-06-01 | 2017-02-15 | 盖尔梅德研究与发展有限公司 | 用于治疗脂肪营养不良的脂肪酸胆汁酸缀合物 |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN116687850A (zh) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3859437A (en) * | 1972-06-02 | 1975-01-07 | Intellectual Property Dev Corp | Reducing cholesterol levels |
| US3856953A (en) * | 1973-05-15 | 1974-12-24 | Intellectual Property Dev Corp | Method of treating fatty liver |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| IT1167479B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido chenodesossicolico |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5278320A (en) | 1992-09-11 | 1994-01-11 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| DE4432708A1 (de) * | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドｘ受容体活性化剤 |
-
2001
- 2001-04-17 IL IL142650A patent/IL142650A/en active IP Right Grant
-
2002
- 2002-04-15 ES ES02761957T patent/ES2289137T3/es not_active Expired - Lifetime
- 2002-04-15 EP EP07002485A patent/EP1790346B1/en not_active Expired - Lifetime
- 2002-04-15 EP EP02761957A patent/EP1379254B1/en not_active Expired - Lifetime
- 2002-04-15 CA CA2703688A patent/CA2703688C/en not_active Expired - Lifetime
- 2002-04-15 PT PT07002485T patent/PT1790346E/pt unknown
- 2002-04-15 CZ CZ2008296A patent/CZ309042B6/cs not_active IP Right Cessation
- 2002-04-15 DK DK02761957T patent/DK1379254T3/da active
- 2002-04-15 UA UA2003109404A patent/UA78699C2/uk unknown
- 2002-04-15 ES ES07002485T patent/ES2328966T3/es not_active Expired - Lifetime
- 2002-04-15 DE DE60220775T patent/DE60220775T2/de not_active Expired - Lifetime
- 2002-04-15 WO PCT/IL2002/000303 patent/WO2002083147A1/en not_active Ceased
- 2002-04-15 AT AT07002485T patent/ATE432705T1/de not_active IP Right Cessation
- 2002-04-15 EA EA200301017A patent/EA007565B1/ru not_active IP Right Cessation
- 2002-04-15 AT AT02761957T patent/ATE365044T1/de active
- 2002-04-15 US US10/474,032 patent/US7501403B2/en not_active Expired - Lifetime
- 2002-04-15 CA CA2444266A patent/CA2444266C/en not_active Expired - Lifetime
- 2002-04-15 MX MXPA03009553A patent/MXPA03009553A/es active IP Right Grant
- 2002-04-15 CN CNB028081870A patent/CN1259918C/zh not_active Expired - Lifetime
- 2002-04-15 PL PL366585A patent/PL205057B1/pl unknown
- 2002-04-15 BR BR0208924-6A patent/BR0208924A/pt not_active Application Discontinuation
- 2002-04-15 PT PT02761957T patent/PT1379254E/pt unknown
- 2002-04-15 JP JP2002580951A patent/JP4324706B2/ja not_active Expired - Lifetime
- 2002-04-15 KR KR1020037013339A patent/KR100883080B1/ko not_active Expired - Lifetime
- 2002-04-15 CZ CZ20032710A patent/CZ300489B6/cs not_active IP Right Cessation
- 2002-04-15 AU AU2002307771A patent/AU2002307771B2/en not_active Expired
- 2002-04-15 PL PL387458A patent/PL211438B1/pl unknown
- 2002-04-15 DE DE60232559T patent/DE60232559D1/de not_active Expired - Lifetime
- 2002-04-15 DK DK07002485T patent/DK1790346T3/da active
- 2002-04-15 NZ NZ528868A patent/NZ528868A/en not_active IP Right Cessation
- 2002-04-15 HU HU0400801A patent/HU230548B1/hu unknown
-
2003
- 2003-10-15 NO NO20034609A patent/NO333910B1/no not_active IP Right Cessation
-
2007
- 2007-01-19 AU AU2007200191A patent/AU2007200191B2/en not_active Expired
- 2007-09-07 CY CY20071101160T patent/CY1106853T1/el unknown
-
2009
- 2009-01-28 US US12/361,291 patent/US8110564B2/en not_active Expired - Lifetime
-
2013
- 2013-09-10 NO NO20131219A patent/NO335087B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8110564B2 (en) | Bile acid or bile salt fatty acid conjugates | |
| AU2002307771A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| Ke et al. | Antioxidant acitivity in vitro and in vivo of the capsule polysaccharides from Streptococcus equi subsp. zooepidemicus | |
| EP1455802B1 (en) | Uses of chitosan oligosaccharides | |
| AP782A (en) | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions. | |
| Mylvaganam et al. | A convenient oxidation of natural glycosphingolipids to their “ceramide acids” for neoglycoconjugation: bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions | |
| AU2008249537A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| US20220280604A1 (en) | Composition for boosting the immune system | |
| US10259833B2 (en) | Natural lipids containing non-oxidizable fatty acids | |
| Mosbach | Regulation of bile acid synthesis | |
| JPH05186353A (ja) | 血清脂質調節剤 | |
| JP2003505504A (ja) | 糞便による脂肪排泄を増加することによる、非ステロール性内因性疎水性物質の排泄を増加する方法 | |
| Gökkuçu et al. | The effect of thymosin fraction 5 on lipid peroxidation in rabbits fed a high-cholesterol diet | |
| HK1003709B (en) | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2016 BY DENNEMEYER + CO. Effective date: 20150318 |
|
| ASS | Change of ownership |
Owner name: GALMED RESEARCH AND DEVELOPMENT LTD, IL Effective date: 20150515 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2017 BY DENNEMEYER + CO. Effective date: 20160322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2018 BY DENNEMEYER + CO. Effective date: 20170331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2019 BY DENNEMEYER + CO Effective date: 20180411 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2021 BY CPA GLOBAL Effective date: 20200227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2022 BY CPA GLOBAL Effective date: 20210304 |
|
| EXPY | Patent expired |